Advisory Board
David A. Katzenstein,
Co-chair
|
David A. Katzenstein, MD
davidkk@stanford.edu
Center for AIDS Research
Division of Infectious Diseases
Stanford University
Stanford, CA
Positions
Associate Professor
Division of Infectious Diseases
Stanford University
Associate Medical Director
Stanford University AIDS Clinical Trial Group
Co-Director
Diagnostic Virology Laboratory
Stanford University Hospital
Date of Birth
January 3, 1952
Education
University of California San Diego (BA Biology 1973)
University of California San Diego School of Medicine (MD 1977)
University of California San Diego (Fellowship, Infectious Diseases, 1980-1981)
University of California Davis (Fellowship, Infectious Diseases, 1981-1983)
Areas of Specialty
Antiretroviral drug resistance, antiretroviral therapy, perinatal transmission prevention, sexually transmitted diseases, post-exposure prophylaxis, HIV vaccinology
Recent Publications
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
Winters MA; Coolley KL; Girard YA; Levee DJ; Hamdan H; Shafer RW; Katzenstein DA; Merigan TC. J Clin Invest. 1998 Nov 15;102(10):1769-75.
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.
Carpenter CC; Fischl MA; Hammer SM; Hirsch MS; Jacobsen DM; Katzenstein DA; Montaner JS; Richman DD; Saag MS; Schooley RT; Thompson MA; Vella S; Yeni PG; Volberding PA. JAMA. 1998 Jul 1;280(1):78-86.
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.
Fiscus SA; Hughes MD; Lathey JL; et al. J Infect Dis. 1998 Mar;177(3):625-33.
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team.
Lathey JL; Hughes MD; Fiscus SA; et al. J Infect Dis. 1998 Mar;177(3):617-24.
Estimating HIV incidence from age-specific prevalence data: comparison with concurrent cohort estimates in a study of male factory workers, Harare, Zimbabwe.
Gregson S; Machekano R; Donnelly CA; Mbizvo MT; Anderson RM; Katzenstein DA. AIDS. 1998 Oct 22;12(15):2049-58.
HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.
Rey D; Hughes M; Pi JT; Winters M; Merigan TC; Katzenstein DA. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):203-8.
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.
Marschner IC; Collier AC; Coombs RW; et al. J Infect Dis. 1998 Jan;177(1):40-7.
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.
Shafer RW; Eisen JA; Merigan TC; Katzenstein DA. J Virol. 1997 Jul;71(7):5441-8.
Adherence as a particular issue with protease inhibitors.
Katzenstein DA. J Assoc Nurses AIDS Care. 1997;8 Suppl:10-7.
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
Shafer RW; Iversen AK; Winters MA; Aguiniga E; Katzenstein DA; Merigan TC. J Infect Dis. 1995 Jul;172(1):70-8.
|
